399 related articles for article (PubMed ID: 29284360)
21. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
22. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
[TBL] [Abstract][Full Text] [Related]
23. Screening for
Chakouri N; Farah C; Matecki S; Amedro P; Vincenti M; Saumet L; Vergely L; Sirvent N; Lacampagne A; Cazorla O
Theranostics; 2020; 10(18):8130-8142. PubMed ID: 32724462
[TBL] [Abstract][Full Text] [Related]
24. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.
Speyer JL; Green MD; Dubin N; Blum RH; Wernz JC; Roses D; Sanger J; Muggia FM
Am J Med; 1985 Apr; 78(4):555-63. PubMed ID: 3838618
[TBL] [Abstract][Full Text] [Related]
25. Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy.
Belham M; Kruger A; Mepham S; Faganello G; Pritchard C
Eur J Heart Fail; 2007 Apr; 9(4):409-14. PubMed ID: 17067854
[TBL] [Abstract][Full Text] [Related]
26. Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.
Uyar D; Kulp B; Peterson G; Zanotti K; Markman M; Belinson J
Gynecol Oncol; 2004 Jul; 94(1):147-51. PubMed ID: 15262133
[TBL] [Abstract][Full Text] [Related]
27. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
Pai VB; Nahata MC
Drug Saf; 2000 Apr; 22(4):263-302. PubMed ID: 10789823
[TBL] [Abstract][Full Text] [Related]
28. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
29. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
Çetin S; Babaoğlu K; Başar EZ; Deveci M; Çorapçıoğlu F
Echocardiography; 2018 Feb; 35(2):234-240. PubMed ID: 29106752
[TBL] [Abstract][Full Text] [Related]
30. Anthracycline cardiotoxicity.
Jones RL; Swanton C; Ewer MS
Expert Opin Drug Saf; 2006 Nov; 5(6):791-809. PubMed ID: 17044806
[TBL] [Abstract][Full Text] [Related]
31. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography.
Villani F; Meazza R; Materazzo C
Anticancer Res; 2006; 26(1B):797-801. PubMed ID: 16739356
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single-center real-world experience.
Mo Z; Deng Y; Bao Y; Liu J; Jiang Y
Cancer Med; 2023 Dec; 12(24):21709-21724. PubMed ID: 38054208
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of cardiomyopathy in acute myeloid leukemia patients treated with anthracyclines.
Mort MK; Sen JM; Morris AL; DeGregory KA; McLoughlin EM; Mort JF; Dunn SP; Abuannadi M; Keng MK
J Oncol Pharm Pract; 2020 Apr; 26(3):680-687. PubMed ID: 31500517
[TBL] [Abstract][Full Text] [Related]
34. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
[TBL] [Abstract][Full Text] [Related]
35. A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.
Sabnis HS; Minson KA; Monroe C; Allen K; Metts JL; Cooper TM; Woods WG; Castellino SM; Keller FG
Leuk Res; 2020 Sep; 96():106421. PubMed ID: 32683126
[TBL] [Abstract][Full Text] [Related]
36. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
Krajinovic M; Elbared J; Drouin S; Bertout L; Rezgui A; Ansari M; Raboisson MJ; Lipshultz SE; Silverman LB; Sallan SE; Neuberg DS; Kutok JL; Laverdière C; Sinnett D; Andelfinger G
Pharmacogenomics J; 2016 Nov; 16(6):530-535. PubMed ID: 26345518
[TBL] [Abstract][Full Text] [Related]
37. Acute cardiomyopathy following a single dose of doxorubicin in a patient with adult T-Cell leukemia/lymphoma.
Farina K; Kalac M; Kim S
J Oncol Pharm Pract; 2021 Jun; 27(4):1011-1015. PubMed ID: 32869692
[TBL] [Abstract][Full Text] [Related]
38. Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial.
Gupta V; Kumar Singh S; Agrawal V; Bali Singh T
Pediatr Blood Cancer; 2018 Nov; 65(11):e27308. PubMed ID: 30009543
[TBL] [Abstract][Full Text] [Related]
39. A prospective comparison of cardiac magnetic resonance imaging and radionuclide ventriculography in the assessment of cardiac function in patients treated with anthracycline-based chemotherapy.
Sipola P; Vanninen E; Jantunen E; Nousiainen T; Kiviniemi M; Hartikainen J; Kuittinen T
Nucl Med Commun; 2012 Jan; 33(1):51-9. PubMed ID: 22044862
[TBL] [Abstract][Full Text] [Related]
40. Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy.
Shureiqi I; Cantor SB; Lippman SM; Brenner DE; Chernew ME; Fendrick AM
Br J Cancer; 2002 Jan; 86(2):226-32. PubMed ID: 11870511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]